Blood tests like pTau217 show growing potential to detect Alzheimer’s disease before symptoms appear, Singapore’s National Neuroscience Institute (NNI) and Duke-NUS Medical School announced today [1, 2, 3]. Alzheimer’s is marked by toxic buildup of amyloid-beta plaques and tau protein tangles in the brain, with biological changes occurring decades before cognitive symptoms arise [1, 2, 3].
NNI currently uses blood tests such as pTau217 to triage patients presenting with early cognitive symptoms. However, experts caution that widespread screening of healthy individuals is not yet recommended due to complex implications [1, 2, 3]. The main value of these blood biomarkers remains diagnosing those with early cognitive impairment [1, 2, 3].
Most previous Alzheimer’s biomarker studies took place in Europe and North America with predominantly Caucasian populations. To address this gap, Singapore institutions are assessing performance of these biomarkers in the nation’s diverse population [1, 2, 3].
In March 2026, NNI and Duke-NUS published a study demonstrating that pTau217 cut-off points aligned closely with those reported in Western cohorts. This supports the test’s broader applicability across different ethnic groups [1, 2, 3]. Associate Professor Adeline Ng of NNI said, "While earlier studies have demonstrated the promise of pTau217 in research cohorts, this study is among the first locally to evaluate its performance in a real-world tertiary memory clinic setting, where patients are more diverse" [1].
The study is one of Singapore’s first real-world evaluations of pTau217 in a tertiary memory clinic, confirming its clinical utility alongside research findings. It signals progress in adapting diagnostic tools to local populations for improved dementia care [1, 2, 3].
Ongoing research in Singapore aims to refine understanding of blood-based biomarkers’ role in early detection. NNI continues to use pTau217 testing as part of clinical assessments for patients with memory concerns.
